Natco Pharma announced on Wednesday plans to invest approximately 250 billion rupees in South Africa. These funds will be directed towards strengthening the company's presence in the African market and entering new geographical areas.
Investment in Subsidiary
The company decided to allocate 140 billion rupees to its wholly-owned subsidiary, Natco Pharma South Africa Proprietary Ltd. The Board of Directors approved this amount at its meeting held on Wednesday.
Increasing Stake in Adcock Ingram
Furthermore, Natco Pharma will increase its stake in the South African company Adcock Ingram Holdings Proprietary Ltd. The stake will rise from the current 35.75 percent to 49 percent. According to regulatory filings, the value of this transaction is estimated at 106.9 billion rupees at the current exchange rate.
To increase its stake, the company will acquire 19,618,825 shares at a price of 92.50 South African Rand (equivalent to 5.89 rupees) per share. The total investment cost will amount to 1.8 billion South African Rand (or 106.9 billion rupees at the current rate), excluding certain related transaction costs and other expenses. This operation is expected to be completed by the end of July 2026.
Goals of Business Expansion
Strengthening participation in Adcock Ingram aims to expand geographical coverage both in South Africa and across the entire African continent. Adcock Ingram, founded in South Africa in 1890, is a pharmaceutical company operating in four segments: prescription drugs, consumer goods, over-the-counter medicines, and hospital products. The company has a diverse product range, including branded and generic formulations, as well as critical care products for hospitals and household goods.

